- Home
- JUNS
as 04-18-2025 1:38pm EST
Stocks
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | JUPITER |
| Market Cap: | 17.6M | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 146.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $19.51 | Next Earning Date: | 05-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest JUPITER NEUROSCIENCES INC News
JUNS Breaking Stock News: Dive into JUNS Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
ACCESS Newswire
a month ago
Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
2 months ago
Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
GlobeNewswire
2 months ago
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
MT Newswires
3 months ago
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules
GlobeNewswire
3 months ago
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
MT Newswires
3 months ago
Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study
GlobeNewswire
3 months ago
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Compare JUNS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JUNS JUPITER NEUROSCIENCES INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.